versal from NDMRs in patients undergoing surgery can be serious because of unintended patient movements that can interfere with surgical procedures and compromise patient safety.
Effects of valproic acid (VPA) on the duration of NDMRs have not been reported to date. VPA is a commonly used antiepileptic with extended indications in cancer, acquired immunodeficiency syndrome, Alzheimer's disease, migraine, and bipolar disorder.
2 Therefore, in this study, we measured the rocuronium requirement (primary outcome) in VPA-premedicated patients undergoing cerebrovascular surgeries, with the primary hypothesis that VPA decreases rocuronium duration, and thus increases its requirement. Magnesium sulphate (MgSO 4 ) is known to potentiate the effects of NDMRs.
3 Thus, we hypothesized that the possible VPA-induced increase in rocuronium requirements is attenuated by MgSO 4 .
Methods
This double-blind randomized controlled trial was approved by the Institutional Review Board and was registered at ClinicalTrials.gov (ID: NCT01460563). Written informed consent was obtained from all participants (age range, 18-65 yr; ASA I -II) undergoing elective craniotomy for aneurysm clipping or for superficial temporal artery -middle cerebral artery anastomosis ( Fig. 1 ). Exclusion criteria were: BMI,18.5 or .24.9 kg m 22 ; neuromuscular, renal, cardiovascular, or Subjects were randomly allocated into three groups, using opaque sealed envelopes: VPA-MgSO 4 (Group VM: VPA premedication and MgSO 4 infusion), VPA control group (Group VC; VPA premedication and no MgSO 4 infusion), and control group (Group C; no VPA premedication and no MgSO 4 infusion). VPA users were administered sodium valproate 1200 and 600 mg i.v. 9 and 2 h before surgery, respectively. Group allocation was coded and concealed until the statistical analyses were complete. The study drugs were prepared and labelled (blue, MgSO 4 ; red, placebo saline) by a nurse who was unaware of the study design. Research personnel who recorded the study variables or who gave the drugs to the patients were blinded to group allocation, study design, and drugs.
The serum VPA concentration was measured immediately before anaesthetic induction in VPA users. Total i.v. anaesthesia was maintained with target-controlled infusion of propofol, titrated to maintain a bispectral index of 40 -60. If mean arterial pressure (MAP) or heart rate (HR) changed to ,80% or .120% of baseline values, remifentanil was titrated at first, and then propofol was titrated, if necessary.
Neuromuscular monitoring adhered to the clinical research consensus. 4 Two paediatric surface electrodes were placed 4 cm apart over the cleansed skin along the ulnar nerve on the side without either an intravascular line or an arterial pressure cuff. The four fingers and the forearm were immobilized, and the position of the acceleration transducer was secured by placing the thumb in a hand adapter (Organon Ltd, Dublin, Ireland). Using a train-of-four (TOF) Watch SX w (Organon Ltd), after a few 2 Hz TOF stimulations (stimulus duration of 200 ms, square wave) and 50 Hz tetanus for 5 s, calibration (implanted mode 2) and stable TOF responses (,5% deviation for 2 min) were ensured in sequence, followed by 2 Hz TOF every 15 s. A rectal temperature .358C and skin temperature on the volar side of the thenar .328C were maintained during the operation.
Subsequently, rocuronium (0.6 mg kg 21 After the operation, patients were given i.v. midazolam (3 mg) and rocuronium (20 mg) for subsequent postoperative radiologic brain imaging, and then transferred to the intensive care unit where they were extubated. The GCS was evaluated at 6 h after operation. Patients received ramosetron (0.3 mg i.v.), followed by patient-controlled analgesia using fentanyl 2000 mg in 0.9% saline (total volume 100 ml) with a basal infusion of 1 ml h 21 , a bolus infusion of 1 ml, and a lock-out time of 10 min. Rescue anti-emetics (ramosetron 0.3 mg i.v.) were given, if necessary. Nicardipine i.v. were used to maintain 80-120% of baseline MAP during the postoperative 48 h. Adverse effects related to MgSO 4 , including respiratory difficulty and arrhythmia, were observed throughout the study period. Drug preparation and collection/measurement/analysis of data were performed by doctors, nurses, and research assistants, who were all blinded to the study. The sample size calculation was based on the unpublished VPA user pilot data, which required rocuronium 0. 
Results
Group VC required a significantly higher total dose of rocuronium and showed a shorter interval between rocuronium (0.15 mg kg 21 ) injections (Table 2 ). There were no significant differences in the rocuronium requirement and injections interval between Groups C and VM (P.0.05). Intraoperative rectal and skin temperatures, MAP, and HR were comparable among the groups (Figs 2-4). MAP was also comparable after operation, but HR was significantly lower in Group VM than that in Group VC (P¼0.02) (Figs 3 and 4) . No statistical difference was found in HR between Groups VM and C or between Groups VC and C (P.0.05). The postoperative incidence of and dose of nicardipine use were, respectively, 10 (63%) and 0.8 (0-6.4) in Group C, and 13 (65%) and 1 (0-9.4) mg in Group VC, and 6 (33%) and 0 (0-1.4) mg in Group VM (P.0.05 for incidence and dose, respectively). Magnesium-related side-effects were not seen in any participant.
Discussion
VPA pre-treatment increased the rocuronium requirement compared with that in the controls. VPA induces the expression of MDR1, a gene encoding a P-glycoprotein (Pgp).
5 Pgp mediates biliary excretion of rocuronium in a rat model. 6 Biliary excretion is a major route of rocuronium elimination. 7 Therefore, it is conceivable that VPA increases Pgp activity, Valproic acid, magnesium, and rocuronium leading to facilitated biliary excretion of rocuronium. Accelerated recovery from rocuronium should be noted in anaesthetic management, particularly for patients undergoing a craniotomy whose head is fixed with pinning devices, because inadvertent movements may result in brain tissue injury or intracranial haemorrhage. This is the first study that has investigated VPA-induced decrease in the duration of NDMRs. A case report described accelerated rocuronium reversal in one patient receiving both VPA and primidone, but the causative agents were unclear. 8 The suggested mechanisms of anticonvulsantinduced resistance to NDMRs include increases in cytochrome P-450 isoenzymes 9 10 and in a1-acid glycoprotein. 1 9 10 However, some studies reported that VPA inhibits 11 or does not increase 12 the isoenzymes. No evidence of increased a1-acid glycoprotein levels with VPA treatment has been observed. In contrast, acute exposure to VPA induces partial neuromuscular block in vitro. 13 This could also account for rocuronium resistance, because such antagonism may cause up-regulation of acetylcholine (Ach) receptors. 1 8 10 If VPA induced neuromuscular block in our study, it might have reduced the magnitude of the TOF twitch response. However, VPA-induced neuromuscular block is subclinical and does not potentiate the effects of NDMRs. 13 Acute administration of anti-epileptics causes neuromuscular block, 10 whereas chronic treatment induces resistance to NDMRs. 1 However, in our study, the first exposure to VPA 
Use of anti-emetics (n) 5 (31%) 9 (45%) 6 (33%) 0.64 was 9 h before the operation. Additionally, VPA treatment for 2-7 days resulted in increased MDR1 expression in rat liver cells. 12 Hence, anaesthetists' consideration for increased rocuronium requirement should not be limited to prolonged administration of VPA.
Patients with epilepsy were excluded from our study because they were likely to have an elevated initial level of Pgp.
14 VPA use in these patients could further increase Pgp and consequently potentiate the acceleration of rocuronium reversal. This should be noted during anaesthetic management of patients with epilepsy, as VPA is a frequently used anticonvulsant.
2
In the present study, the VPA-induced increase in the rocuronium requirement was reduced to control levels by MgSO 4 . Magnesium potentiates NDMRs mainly by decreasing prejunctional Ach release. 15 As rocuronium is a competitive antagonist of Ach, the Mg-induced Ach reduction may offset the rocuronium elimination facilitated by VPA. Thus, MgSO 4 administration may reduce the risk for unexpected movements caused by accelerated rocuronium reversal. Additionally, MgSO 4 decreased the frequency of rocuronium injections in VPA users in this study, which may improve anaesthetists' convenience. The use of MgSO 4 may have another advantage in terms of postoperative analgesia by antagonizing the NMDA receptor, preventing enhanced NMDA signalling, and inhibiting calcium conductance. 15 In previous studies, 3 16 intraoperative MgSO 4 infusion provided pain relief during the immediate postoperative 48 h. The analgesic effects might have led to significantly lower HR in Group VM compared with Group VC in the present study. However, postoperative MAP was comparable between the groups. One possible explanation is that nicardipine controls hypertension, but cannot stabilize HR. 17 The administration of MgSO 4 did not cause symptoms of hypermagnesemia in the present study, consistent with our previous reports.
3 16 18 In the previous reports, the same dose of MgSO 4 was used, and the immediate postoperative Mg concentration was 1.3 -1.5, which decreased to 1.06 at 6 h after operation. The reference range of Mg (mmol litre 21 ) is 0.7-1.3, and the therapeutic ranges are 1.1-1.5
for preeclampsia 19 and 2-2.5 for subarachnoid haemorrhage. 20 Thus, Mg 2+ concentrations (mean, 0.78; maximum, 0.93) in our patients are considered below toxic level. Moreover, patients undergoing cerebrovascular surgery can be at risk for hypomagnesemia owing to the use of diuretics 21 and polyuria. 15 22 However, Mg-related possible complications should be considered, particularly in renal insufficiency. 15 Comparable extubation times and postoperative GCSs among the groups in this study (Table 2) suggest that MgSO 4 may not necessarily affect postoperative recovery. In our previous study, time from skin closure to tracheal extubation was not prolonged when MgSO 4 was used intraoperatively in the same dose and regimen with that of the present study. 16 In addition, MgSO 4 60 mg kg 21 delayed reversal of rocuronium-induced neuromuscular block from 24.7 (control) to 28.5 min. 23 Such delay may not have a significant clinical impact on surgeries of long duration, including cerebrovascular surgeries. However, MgSO 4 can possibly delay postoperative recovery, 24 and therefore patients receiving MgSO 4 during the surgery may require close observation during the recovery period. One limitation of this study is that the effect of VPA on rocuronium onset was not measured, which might have further elucidated VPA effects on rocuronium resistance, had it been measured. As for the effect of magnesium, it was recently reported that rocuronium onset was accelerated by MgSO 4 . 23 In conclusion, VPA increased the rocuronium requirement, and intraoperative MgSO 4 infusion attenuated this increase.
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